Synairgen plc

LSE SNG.L

Synairgen plc Price to Sales Ratio (P/S) on January 14, 2025

Synairgen plc Price to Sales Ratio (P/S) is NA on January 14, 2025, a NA change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Synairgen plc 52-week high Price to Sales Ratio (P/S) is NA on January 14, 2025, which is NA below the current Price to Sales Ratio (P/S).
Synairgen plc 52-week low Price to Sales Ratio (P/S) is NA on January 14, 2025, which is NA below the current Price to Sales Ratio (P/S).
Synairgen plc average Price to Sales Ratio (P/S) for the last 52 weeks is NA.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

LSE: SNG.L

Synairgen plc

CEO	Mr. Richard Marsden
IPO Date	Oct. 26, 2004
Location	United Kingdom
Headquarters	Mailpoint 810
Employees	36
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.

Key trends

Past 5 years